ES2174144T3 - Anticuerpos contra el factor de crecimiento derivado de plaquetas en el tratamiento de la reestenosis. - Google Patents

Anticuerpos contra el factor de crecimiento derivado de plaquetas en el tratamiento de la reestenosis.

Info

Publication number
ES2174144T3
ES2174144T3 ES97106298T ES97106298T ES2174144T3 ES 2174144 T3 ES2174144 T3 ES 2174144T3 ES 97106298 T ES97106298 T ES 97106298T ES 97106298 T ES97106298 T ES 97106298T ES 2174144 T3 ES2174144 T3 ES 2174144T3
Authority
ES
Spain
Prior art keywords
plates
reset
treatment
growth factor
antibodies against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97106298T
Other languages
English (en)
Inventor
Russell Ross
Michael A Reidy
Elaine W Raines
Volkhard Lindner
Gordon A A Ferns
Christopher Jackson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Application granted granted Critical
Publication of ES2174144T3 publication Critical patent/ES2174144T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

METODOS PARA INHIBIR LA ESTENOSIS VASCULAR EN UN MAMIFERO, INCLUYENDO LA RESTENOSIS TRAS LA ELIMINACION QUIRURGICA DE LAS PLACAS ATEROSCLEROTICAS O EL BYPASS QUIRURGICO DE ARTERIAS OCLUIDAS. LA INHIBICION SE CONSIGUE MEDIANTE LA ADMINISTRACION DE ANTICUERPOS ANTI-FACTOR DE CRECIMIENTO, INCLUYENDO LOS ANTICUERPOS ANTI-FGF Y ANTICUERPOS ANTI-PDGF.
ES97106298T 1991-01-17 1992-01-17 Anticuerpos contra el factor de crecimiento derivado de plaquetas en el tratamiento de la reestenosis. Expired - Lifetime ES2174144T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64175891A 1991-01-17 1991-01-17

Publications (1)

Publication Number Publication Date
ES2174144T3 true ES2174144T3 (es) 2002-11-01

Family

ID=24573729

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97106298T Expired - Lifetime ES2174144T3 (es) 1991-01-17 1992-01-17 Anticuerpos contra el factor de crecimiento derivado de plaquetas en el tratamiento de la reestenosis.
ES92905617T Expired - Lifetime ES2117046T3 (es) 1991-01-17 1992-01-17 Anticuerpo anti-factor de crecimiento en el tratamiento de estenosis vascular.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES92905617T Expired - Lifetime ES2117046T3 (es) 1991-01-17 1992-01-17 Anticuerpo anti-factor de crecimiento en el tratamiento de estenosis vascular.

Country Status (10)

Country Link
US (1) US5648076A (es)
EP (2) EP0798002B1 (es)
JP (2) JP3667752B2 (es)
AT (2) ATE164521T1 (es)
AU (1) AU665529B2 (es)
CA (1) CA2100876A1 (es)
DE (2) DE69224983T2 (es)
DK (2) DK0573510T3 (es)
ES (2) ES2174144T3 (es)
WO (1) WO1992012734A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
CN1186439A (zh) * 1995-06-07 1998-07-01 森特克公司 血小板特异性的嵌合性免疫球蛋白及其使用方法
US7241568B2 (en) 1996-04-03 2007-07-10 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
AU6497198A (en) * 1997-02-14 1998-09-08 Boehringer Mannheim Gmbh Improved method for the reduction of neointima formation after angioplasty
EP1422243B1 (en) * 2001-06-28 2008-04-23 Kyowa Hakko Kogyo Co., Ltd Humanized antibody against fibroblast growth factor-8 and fragment of the antibody
PL1680140T3 (pl) * 2003-10-16 2011-11-30 Imclone Llc Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia
US9339593B2 (en) * 2007-01-11 2016-05-17 Robert L. Bjork, JR. Drug-eluting coronary artery stent coated with anti-platelet-derived growth factor antibodies overlaying extracellular matrix proteins with an outer coating of anti-inflammatory (calcineurin inhibitor) and/or anti-proliferatives
JP5602432B2 (ja) * 2007-01-11 2014-10-08 ロバート ラマール ジュニア ビョーク 経皮的冠動脈インターベンション用の多剤溶出冠動脈ステント
WO2016149103A1 (en) * 2015-03-13 2016-09-22 The Regents Of The University Of California Monoclonal antibody for prevention and/or treatment of astrovirus disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE116373T1 (de) * 1987-03-03 1995-01-15 Takeda Chemical Industries Ltd Monoklonaler antikörper, hybridomen, ihre herstellung und ihre verwendung.
CA1339356C (en) * 1988-02-02 1997-08-26 Lewis T. Williams Human platelet-derived growth factor receptor
US5268358A (en) * 1988-12-08 1993-12-07 Cor Therapeutics, Inc. PDGF receptor blocking peptides
AU6605690A (en) * 1989-10-27 1991-05-31 Du Pont Merck Pharmaceutical Company, The Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity
JP4350370B2 (ja) * 2002-12-27 2009-10-21 株式会社半導体エネルギー研究所 電子回路及び電子機器

Also Published As

Publication number Publication date
WO1992012734A1 (en) 1992-08-06
DE69232579T2 (de) 2002-08-22
JP3667752B2 (ja) 2005-07-06
EP0573510B1 (en) 1998-04-01
DE69224983D1 (de) 1998-05-07
AU1327492A (en) 1992-08-27
EP0573510A1 (en) 1993-12-15
ES2117046T3 (es) 1998-08-01
DE69232579D1 (de) 2002-05-29
DE69224983T2 (de) 1998-07-30
ATE216592T1 (de) 2002-05-15
ATE164521T1 (de) 1998-04-15
DK0573510T3 (da) 1998-04-27
DK0798002T3 (da) 2002-08-19
JPH06504551A (ja) 1994-05-26
CA2100876A1 (en) 1992-07-18
EP0798002A1 (en) 1997-10-01
JP2002316945A (ja) 2002-10-31
EP0798002B1 (en) 2002-04-24
US5648076A (en) 1997-07-15
AU665529B2 (en) 1996-01-11

Similar Documents

Publication Publication Date Title
TR199801919T2 (xx) Rapamisin t�revlerinin damar hastal�klar� ve yabanc� doku naklinde kullan�m�.
DE69435137D1 (de) Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
NO861624L (no) Roerformet proteseartikkel.
DE69433381D1 (de) Verfahren zur behandlung atherosklerose oder restenose mit hilfe eines mikrotubulusstabilisators
DK56291D0 (da) Anvendelse af gamma-interferon til fremstilling af et laegemiddel til behandling af vasculaer stenosis
DE122005000005I2 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz
ATE94387T1 (de) Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung.
DE69731652D1 (de) Verfahren zur behandlung von endothelialen verletzungen
ES2174144T3 (es) Anticuerpos contra el factor de crecimiento derivado de plaquetas en el tratamiento de la reestenosis.
DE60231522D1 (de) Behandlung und vorbeugung von insulin-produzierende zelltransplantatabstossung
DK0854709T4 (da) Anvendelse af boswelliasyre og derivater deraf til hæmning af normal og foröget leukocytelastase- eller plasminaktivitet
NO894222L (no) Fremgangsmaater for behandling og profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer for anvendelse i nevnte metoder.
ES2061853T3 (es) Utilizacion de inhibidores de la eca contra la formacion de neointimas despues de lesion vascular.
EA199900724A1 (ru) Способы лечения, профилактики и защиты кровеносных сосудов от повреждений (варианты), способы лечения и профилактики различных видов гипертензии, атеросклероза (варианты)
ATE128871T1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
DE69124534T2 (de) Katecholderivate, deren physiologisch unbedenkliche Salze, Ester und deren Verwendung bei der Behandlung von durch Lipidperoxidation verursachten Gewebeschäden
DE69635131D1 (de) Verwendung von beta-interferon zur behandlung der restenose
Rebane et al. Effectiveness of Reoperations on Infrainguinal Arteries
DE68904195D1 (de) Paromomycin oder seine derivate zur parenteralen behandlung von parasitaeren erkrankungen beim menschen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 798002

Country of ref document: ES